NCT07054190 - A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

November 8, 2027

Conditions

Breast Cancer

Interventions

DRUG

Inavolisib

Inavolisib will be administered as per the schedule specified in the arms

DRUG

Ribociclib

Ribociclib will be administered as per the schedule specified in the arms

DRUG

Letrozole

Letrozole will be administered as per the schedule specified in the arms

Trial Locations (8)

46010

RECRUITING

Hospital Clínico Universitario de Valencia, Valencia

H2X 0C2

RECRUITING

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

H3T1E2

RECRUITING

Jewish General Hospital, Montreal

H4A 3J1

RECRUITING

McGill University Health Center, Montreal

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

05505

RECRUITING

Asan Medical Center., Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY